The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Jun 27, 2023 • 1h
Ep138: Jodie Morrison on Becoming a Biotech CEO
Jodie Morrison, acting CEO of Q32Bio, on becoming a biotech CEO.
Jun 14, 2023 • 57min
Ep137: Aaron Ring on Immunotherapy for Cancer & More
Aaron Ring, a scientist at Yale moving to the Fred Hutchinson Cancer Center, on applying immunology and protein engineering for cancer therapy and more.
May 30, 2023 • 53min
Ep136: Deborah Palestrant on Building Biotech Startups
Deborah Palestrant, partner at 5AM Ventures and head of the 4:59 initiative, on building biotech startups.
11 snips
May 8, 2023 • 1h 4min
Ep135: John Maraganore on Developing a New Class of Medicines
John Maraganore, founding CEO of Alnylam Pharmaceuticals who led development of RNA interference therapeutics. He recounts the long road to creating a new drug class. Topics include RNAi delivery challenges, strategic use of LNPs and GalNAc conjugates, target selection and rare-disease commercial strategy, clinical setbacks and recoveries, partnerships that validated the approach, and how computation and AI are accelerating discovery.
Apr 24, 2023 • 1h 16min
Ep134: Emile Nuwaysir on In Vivo Gene Editing Therapies
Emile Nuwaysir, CEO of Boston-based Ensoma, on developing off-the-shelf in vivo gene editing therapies.
Apr 12, 2023 • 1h 11min
Ep133: Catherine Stehman-Breen on Epigenetic Editing Therapies
Catherine Stehman-Breen, CEO of Boston-based Chroma Medicine, on developing epigenetic editing therapies.
Mar 28, 2023 • 1h 6min
Ep132: Eric Dobmeier on Treating Kidney Disease
Eric Dobmeier, CEO of Seattle-based Chinook Therapeutics, on new strategies for treating kidney diseases.
Mar 14, 2023 • 1h 6min
Ep131: Ryan Watts on Neuroscience Drug R&D
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
Feb 28, 2023 • 1h 9min
Ep130: David Hallal on a Life in Biotech & the Cell Therapy Wave
David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
4 snips
Feb 14, 2023 • 1h 12min
Ep129: Joanne Smith-Farrell on Engineered B-Cell Therapies
Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.


